NCT06230822View on ClinicalTrials.gov

Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF)

PHASE1RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

February 29, 2024

Primary Completion Date

January 31, 2025

Study Completion Date

December 31, 2026

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

VUM02 Injection

VUM02 Injection will be administered intravenously every 3 days for a total of 3 doses.

Trial Locations (4)

Unknown

RECRUITING

Peking University Third Hospital, Beijing

RECRUITING

West China Hospital of Sichuan University, Chengdu

RECRUITING

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

RECRUITING

The First People's Hospital of Kashi Prefecture, Xinjiang, Kashgar

All Listed Sponsors
lead

Wuhan Optics Valley Vcanbiopharma Co., Ltd.

INDUSTRY